UC researchers secure seven-figure contract from Department of Defense
Cincinnati Business Courier: Military support advances clinical trials for brain injury device
Launched in 2017 as one of the first initiatives funded by the University of Cincinnati’s Technology Accelerator for Commercialization, now the UC Venture Lab, Sense Neuro Diagnostics, a MedTech startup, has secured a $2 million contract from the United States Department of Defense, the Cincinnati Business Courier reported.
Founded by UC physicians including Opeolu Adeoye, MD, George Shaw, MD, PhD, and Matthew Flaherty, MD, this latest round of funding for Sense Neuro supports clinical trials set to commence next summer to advance their pioneering brain injury detection device, NeuroHawk.
The company has grown substantially since it launched, receiving over $18 million from various sources, such as the U.S. Army Medical Research and Development Command, the Cleveland Clinic, St. Elizabeth Healthcare and Queen City Angels.
"Sense Neuro Diagnostics embodies UC’s mission to transform research into real-world impact,” said Geoffrey Pinski, assistant vice president of Technology Transfer at UC’s 1819 Innovation Hub. “Their progress shows the potential for university IP to address urgent health care needs, bringing our innovations to those who need them most.”
How it works
Designed to detect traumatic brain injuries (TBIs) and hemorrhages in specific regions of the brain, NeuroHawk’s technology aims to provide rapid, reliable diagnoses on the front lines of care. Clinical trials will span two-and-a-half years and involve local medical institutions including UC along with several testing sites across the country.
NeuroHawk is a noninvasive, portable wireless headset that passes radio frequency through the brain, scanning and analyzing how signals are affected by changes in brain tissue. The device offers rapid detection of TBIs, a crucial tool for active-duty military in the field when seconds matter.
Sense Neuro’s CEO, Geoffrey Klass, affirms the company’s commitment to addressing the significant medical need for quick and precise TBI diagnosis, a prevalent issue among U.S. service members.
With clinical trials on the horizon and a robust network of support, Sense Neuro Diagnostics is advancing its mission to revolutionize TBI diagnostics for both military and civilian applications.
The NeuroHawk is poised to play a transformative role in the timely diagnosis and treatment of brain injuries.
Read the full story in the Cincinnati Business Courier. If subscription fees are required, email laradm@ucmail.uc.edu for a PDF of the story.
Featured image at top: Members of UC’s Army ROTC depart from Lunken Airport by Chinook and Blackhawk helicopter for a weekend drill. Photo/Abby Hardesty
Innovation Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Related Stories
The subtle changes in hearing you should never ignore
July 24, 2026
It’s easy to dismiss changes in hearing as minor. But as The Washington Post recently reported, these symptoms could also signal a medical emergency that many people don’t recognize — known as sudden sensorineural hearing loss, a rapid decline in hearing that occurs suddenly or over a few days.
UC experts say proper produce washing is key defense against Cyclospora
July 24, 2026
Hamilton County Public Health reports confirmed cases of cyclosporiasis, as concerns persist. Cyclospora is a parasite that can cause a stomach illness lasting days — sometimes even weeks. University of Cincinnati medical experts say it is usually linked to contaminated water or food, often fresh produce.
What are the options for male birth control?
July 24, 2026
Despite major advances in contraception during the past several decades, responsibility for pregnancy prevention falls largely on women. As recently reported in Endocrinology Advisor, a new generation of male contraceptive candidates is advancing into early- and mid-stage clinical trials.